ATLANTA, May 27, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts regarding the impact of the FDA’s Warning Letter on Viatris’ financials. If you purchased shares of Viatris between August 8, 2024 and February 26, 2025, and experienced a significant loss on that investment, you are e ...

PHILADELPHIA, May 27, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represent ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, hindering the company from manufacturing and distributing key products, including Lenalidomide [4]. - In the Q4 2024 results released on February 27, 2025, Viatris disclosed that the inspection's repercussions would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Viatris Inc. (NASDAQ: VTRS)? Did you purchase your shares between August 8, 2024 and February 26, 2025, inclusive? Did you lose money in y ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must move the Court by June 3, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that would prevent shipping eleven products [4] - Defendants allegedly made materially false statements and concealed adverse facts about the impact of the warning letter on Viatris' financials, leading to artificially inflated security prices [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the inflated prices at which they purchased Viatris securities [5]

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational status and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until June 3, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint alleges that Viatris misrepresented its facilities as being in "good operating condition" and committed to high-quality manufacturing standards, despite a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has significantly impacted Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results, Viatris disclosed that the negative impact from the Indore facility's inspection would reduce 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must move the Court by June 3, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that would prevent shipping eleven products [4] - Defendants allegedly downplayed the impact of the FDA warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection and remediation efforts [5] - The misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true information became public [5]

PHILADELPHIA, May 23, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired VIATRIS securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represent ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - Following the disclosure of the inspection's ramifications, Viatris projected a revenue decrease of approximately $500 million and an earnings reduction of about $385 million for 2025 [5]. - On February 27, 2025, Viatris's stock price fell roughly 15%, from $11.24 per share to $9.53 per share, in response to the negative news [5].

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud impacting investors between August 8, 2024, and February 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying its significance as a "minor headwind" [2] - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024 on February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53 per share, a decline of approximately 15.21% in one day [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]